Flossbach Von Storch AG continued to hold its position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,220 shares of the biopharmaceutical company’s stock at the end of the first quarter. Flossbach Von Storch AG’s holdings in Gilead Sciences were worth $219,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Meridian Wealth Management LLC purchased a new position in Gilead Sciences during the fourth quarter worth approximately $216,000. First Allied Advisory Services Inc. boosted its position in Gilead Sciences by 0.5% in the fourth quarter. First Allied Advisory Services Inc. now owns 98,360 shares of the biopharmaceutical company’s stock worth $7,044,000 after buying an additional 463 shares during the last quarter. Employees Retirement System of Texas boosted its position in Gilead Sciences by 8.0% in the fourth quarter. Employees Retirement System of Texas now owns 350,900 shares of the biopharmaceutical company’s stock worth $25,128,000 after buying an additional 26,000 shares during the last quarter. Mayo Investment Advisers LLC boosted its position in Gilead Sciences by 144.6% in the fourth quarter. Mayo Investment Advisers LLC now owns 85,200 shares of the biopharmaceutical company’s stock worth $6,101,000 after buying an additional 50,362 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Gilead Sciences by 170.9% in the fourth quarter. Renaissance Technologies LLC now owns 5,274,948 shares of the biopharmaceutical company’s stock worth $377,739,000 after buying an additional 3,327,900 shares during the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.680% during mid-day trading on Tuesday, hitting $73.305. The stock had a trading volume of 3,878,454 shares. The firm has a market cap of $95.73 billion, a PE ratio of 7.962 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10. The stock’s 50-day moving average is $72.43 and its 200 day moving average is $68.75.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the business earned $3.08 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
GILD has been the subject of a number of research analyst reports. William Blair reissued an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Credit Suisse Group AG reissued an “outperform” rating and set a $79.00 price target on shares of Gilead Sciences in a report on Friday, May 5th. Leerink Swann reissued a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a report on Friday, July 28th. Twelve analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $80.31.
In other news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at $10,174,112. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
